Quantinno Capital Management LP cut its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 28.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 730,567 shares of the medical technology company’s stock after selling 283,724 shares during the quarter. Quantinno Capital Management LP’s holdings in Medtronic were worth $63,304,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the business. Madison Asset Management LLC increased its holdings in shares of Medtronic by 15.0% in the 4th quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock valued at $18,752,000 after acquiring an additional 25,527 shares during the last quarter. Ticino Wealth purchased a new stake in Medtronic during the fourth quarter worth approximately $2,049,000. First Eagle Investment Management LLC boosted its holdings in Medtronic by 0.4% in the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company’s stock valued at $939,009,000 after purchasing an additional 40,196 shares in the last quarter. KBC Group NV boosted its holdings in Medtronic by 5.2% in the fourth quarter. KBC Group NV now owns 430,508 shares of the medical technology company’s stock valued at $41,354,000 after purchasing an additional 21,384 shares in the last quarter. Finally, Cerity Partners LLC increased its stake in Medtronic by 12.7% in the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock valued at $75,988,000 after purchasing an additional 89,111 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.
Key Headlines Impacting Medtronic
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Medtronic completed its $650 million acquisition of SPR Therapeutics and launched the ViaVerte system at ASPN 2026. The deal expands the company’s non-opioid pain-management portfolio and could provide a new avenue for growth in pain therapy. Medtronic Completes $650 Million SPR Deal And Launches ViaVerte
- Positive Sentiment: Brokerages have assigned Medtronic an average “Moderate Buy” recommendation, indicating that analysts generally see upside or support at current valuation levels. Medtronic Given Average Recommendation of Moderate Buy
- Neutral Sentiment: Valuation analysis suggests MDT is near fair value on a discounted-cash-flow basis but may screen as undervalued on earnings multiples. Shares are near a five-year low after an approximately 25% five-year decline, which may attract value investors, though the analysis notes execution and growth risks. Medtronic Stock May Be Fairly Valued As Shares Sit Near A 5 Year Low
- Neutral Sentiment: MDT recently outperformed the broader market in a session that ended at $84.22, reflecting improving short-term momentum but offering no major fundamental catalyst by itself. Medtronic Outpaces Stock Market Gains
- Negative Sentiment: Medtronic initiated a voluntary Class II recall of its DLP One-Piece Pediatric Arterial Cannula after two complaints involving loose foreign material with trace blood levels. The recall may raise product-quality, regulatory and reputational concerns, although its impact on company-wide results is not yet clear. Is Medtronic Fairly Valued After Its Pediatric Cannula Recall?
Medtronic Price Performance
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. The firm had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.94 EPS for the current year.
Medtronic Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were issued a $0.72 dividend. The ex-dividend date of this dividend was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s dividend payout ratio is currently 77.21%.
Analysts Set New Price Targets
A number of research firms have weighed in on MDT. Jefferies Financial Group reissued a “hold” rating and set a $88.00 price objective on shares of Medtronic in a report on Thursday, June 4th. Evercore set a $105.00 target price on shares of Medtronic in a report on Monday, July 6th. Sanford C. Bernstein dropped their target price on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday, June 4th. Rothschild & Co Redburn cut their price target on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a research note on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.83.
View Our Latest Analysis on MDT
Insider Buying and Selling at Medtronic
In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.26% of the company’s stock.
Medtronic Profile
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Featured Articles
- Five stocks we like better than Medtronic
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
